Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China

Objective: Niraparib improved survival in platinum-sensitive recurrent ovarian cancer (PSROC) patients versus routine surveillance, accompanied by increased costs. Based on the NORA trial, we evaluated for the first time the cost-effectiveness of maintenance niraparib with individualized starting do...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yin, Xiao, Di, Li, Shuishi, Liu, Shao, Zhang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416097/
https://www.ncbi.nlm.nih.gov/pubmed/37576812
http://dx.doi.org/10.3389/fphar.2023.1198585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416097/
https://www.ncbi.nlm.nih.gov/pubmed/37576812
http://dx.doi.org/10.3389/fphar.2023.1198585

Ejemplares similares